Immune Mediated Inflammatory Disorders
|Event Date/Time: Sep 20, 2003||End Date/Time: Sep 20, 2003|
|Registration Date: Sep 12, 2003|
|Early Registration Date: Sep 09, 2003|
The central and important role of tumor necrosis factor alpha in the development of inflammation and tissue damage in autoimmune and systemic inflammatory disorders is well defined. New and powerful biologic drugs have been developed that block this pro-inflammatory cytokine and this had led to a new age of effective therapy for many diseases such as rheumatoid arthritis, inflammatory bowel disease and many others. This program is needed in order to communicate important information to primary care and specialist physicians with regard to the safe and effective way to employ these new medications and their potential side effects.
This program is designed for Rheumatologists, Dermatologists, Gastroenterologists, Primary Care Physicians, Internal Medicine Physicians, Residents and Fellows.
The purpose of this session is to bring together an expert panel of clinicians and investigators to review the most up-to-date information regarding the broad indications for, clinical results with and potential side effects of tumor necrosis factor alpha blockers.
At the conclusion of the course the participant will be able to:
1. Delineate the biology of TNF and the interactions of TNF, lymphotoxin with TNF receptors.
2. Explain the role of TNF in pathophysiology of inflammatory and autoimmune diseases.
3. Discuss the chemistry, structure and mechanisms of action of the currently available and future TNF inhibitors.
4. Describe the role of TNF inhibitors in the treatment of rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease.
5. Appreciate the emerging use of TNF inhibitors in inflammatory skin diseases such as psoriasis and graft versus host diseases as well as in other systemic or local inflammatory disorders such as ankylosing spondylitis, uveitis, interstitial lung disease, sarcoidosis, and inflammatory myopathies.
6. Demonstrate the likelihood and types of infectious complications, such as tuberculosis during treatment with TNF inhibitors.
7. Describe non-infectious complications that may potentially result from TNF inhibition.
7:30 Registration & Breakfast
7:55 Opening Remarks
Stephen A. Paget, MD
8:00 The history, basic science and biology of TNF
Lionel B. Ivashkiv, MD
8:30 Current TNF inhibitors employed in the treatment of in rheumatologic diseases such as rheumatoid arthritis and psoriatic arthritis
Kenneth T. Calamia, MD
9:00 Q & A
9:15 Overview on the Immunologic Basis for Biologic Therapy in Psoriasis
Daniel N. Sauder, MD
9:45 Q & A
10:00 TNF inhibitors in gastrointestinal diseases
Ellen J. Scherl, MD
10:30 Q & A
11:00 The use of anti-TNF Agents in systemic and local inflammatory disorders such as ankylosing spondylitis, uveitis, sarcoidosis, interstitial lung disease and inflammatory myopathies and emerging uses in rheumatic diseases
Kenneth T. Calamia, MD
11:30 Q & A
11:45 Complications and side effects of anti-TNF therapy
Stephen A. Paget, MD
12:15 Q & A
Hospital for Special Surgery and Weill Medical College of Cornell University gratefully acknowledge funding support for this program with a generous unrestricted educational grant from Centocor.
Weill Medical College of Cornell University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Weill Medical College of Cornell University designates this educational activity for a maximum of 4.25 credits in Category 1 towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.
AAPA accepts AMA Category 1 credit for the PRA from organizations accredited by ACCME.
The CME Evaluation Form and Needs Assessment Form are included in your syllabus. Completed forms will be collected at the end of this program. We encourage you to complete both forms, which will allow us to assess the degree to which the overall program fulfills its CME mission. It will also guide the planning of future activities and permit rational decisions about improving the educational program
It is the policy of Weill Medical College of Cornell University to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose to the audience any potential, apparent, or real conflict of interest related to their contribution to the activity, and any discussions of an unlabeled or uninvestigated use of any commercial product or device not yet approved in the United States.